File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome

TitlePilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome
Authors
KeywordsLupus
Membranous
Mycophenolate Mofetil
Nephritis
Tacrolimus
Issue Date2012
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/NEP
Citation
Nephrology, 2012, v. 17 n. 4, p. 352-357 How to Cite?
AbstractAim: This pilot study compared mycophenolate mofetil (MMF) and tacrolimus (Tac) in the treatment of severe membranous lupus nephritis (MLN). Method: This was a 24 month prospective, randomized, open-label multi-centre exploratory study on Chinese patients with biopsy-proven pure Class V MLN with nephrotic syndrome. Patients were randomized to treatment with either MMF or Tac, both in combination with prednisolone and the efficacy and tolerability outcomes were examined. Results: Sixteen patients were included, seven in the MMF and nine in the Tac treatment arm. At 24 months the complete response, partial response and overall response rates were 57.1% vs. 11.1% (P = 0.049), 14.3% vs. 44.4% (P = 0.197) and 71.4% vs. 55.6% (P = 0.515) in the MMF and Tac groups, respectively. The two groups had similar reduction of proteinuria and longitudinal profiles of serum albumin and creatinine levels. Serum creatinine remained stable in both groups, except in two patients who had a transient increase associated with high Tac blood levels. Adverse events in the MMF group included herpes zoster in one patient and reversible leucopenia in another, while in the Tac group four patients had severe infections and one developed new onset diabetes. No relapse occurred during the study period. Conclusion: Both MMF and Tac when combined with corticosteroids are effective treatment options for severe MLN. © 2012 Asian Pacific Society of Nephrology.
Persistent Identifierhttp://hdl.handle.net/10722/163479
ISSN
2015 Impact Factor: 1.796
2015 SCImago Journal Rankings: 0.894
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYap, DYHen_US
dc.contributor.authorYu, Xen_US
dc.contributor.authorChen, XMen_US
dc.contributor.authorLu, Fen_US
dc.contributor.authorChen, Nen_US
dc.contributor.authorLi, XWen_US
dc.contributor.authorTang, CSOen_US
dc.contributor.authorChan, TMen_US
dc.date.accessioned2012-09-05T05:31:49Z-
dc.date.available2012-09-05T05:31:49Z-
dc.date.issued2012en_US
dc.identifier.citationNephrology, 2012, v. 17 n. 4, p. 352-357en_US
dc.identifier.issn1320-5358en_US
dc.identifier.urihttp://hdl.handle.net/10722/163479-
dc.description.abstractAim: This pilot study compared mycophenolate mofetil (MMF) and tacrolimus (Tac) in the treatment of severe membranous lupus nephritis (MLN). Method: This was a 24 month prospective, randomized, open-label multi-centre exploratory study on Chinese patients with biopsy-proven pure Class V MLN with nephrotic syndrome. Patients were randomized to treatment with either MMF or Tac, both in combination with prednisolone and the efficacy and tolerability outcomes were examined. Results: Sixteen patients were included, seven in the MMF and nine in the Tac treatment arm. At 24 months the complete response, partial response and overall response rates were 57.1% vs. 11.1% (P = 0.049), 14.3% vs. 44.4% (P = 0.197) and 71.4% vs. 55.6% (P = 0.515) in the MMF and Tac groups, respectively. The two groups had similar reduction of proteinuria and longitudinal profiles of serum albumin and creatinine levels. Serum creatinine remained stable in both groups, except in two patients who had a transient increase associated with high Tac blood levels. Adverse events in the MMF group included herpes zoster in one patient and reversible leucopenia in another, while in the Tac group four patients had severe infections and one developed new onset diabetes. No relapse occurred during the study period. Conclusion: Both MMF and Tac when combined with corticosteroids are effective treatment options for severe MLN. © 2012 Asian Pacific Society of Nephrology.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/NEPen_US
dc.relation.ispartofNephrologyen_US
dc.subjectLupusen_US
dc.subjectMembranousen_US
dc.subjectMycophenolate Mofetilen_US
dc.subjectNephritisen_US
dc.subjectTacrolimusen_US
dc.titlePilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndromeen_US
dc.typeArticleen_US
dc.identifier.emailYap, DY:desmondy@hku.hken_US
dc.identifier.emailChan, TM:dtmchan@hku.hken_US
dc.identifier.authorityYap, DY=rp01607en_US
dc.identifier.authorityChan, TM=rp00394en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1440-1797.2012.01574.xen_US
dc.identifier.pmid22295934-
dc.identifier.scopuseid_2-s2.0-84860151628en_US
dc.identifier.hkuros209987-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84860151628&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume17en_US
dc.identifier.issue4en_US
dc.identifier.spage352en_US
dc.identifier.epage357en_US
dc.identifier.isiWOS:000305578600006-
dc.publisher.placeAustraliaen_US
dc.identifier.scopusauthoridYap, DY=25958532000en_US
dc.identifier.scopusauthoridYu, X=7404114196en_US
dc.identifier.scopusauthoridChen, XM=35309818300en_US
dc.identifier.scopusauthoridLu, F=7402968373en_US
dc.identifier.scopusauthoridChen, N=55058311500en_US
dc.identifier.scopusauthoridLi, XW=37050035700en_US
dc.identifier.scopusauthoridTang, CS=8681865300en_US
dc.identifier.scopusauthoridChan, TM=7402687700en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats